Technical and Clinical Outcomes After Transcatheter Edge-to-Edge Repair of Mitral Regurgitation in Male and Female Patients: Is Equality Achieved?

• Published in: Journal of the American Heart Association Vol. 13; no. 11; p. e032706
• Main Authors: Biasco, Luigi, Tersalvi, Gregorio, Klersy, Catherine, Benfari, Giovanni, Biaggi, Patric, Corti, Roberto, Curti, Moreno, Gaemperli, Oliver, Jeger, Raban, Maisano, Francesco, Mueller, Olivier, Naegeli, Barbara, Noble, Stephane, Praz, Fabien, Toggweiler, Stefan, Valgimigli, Marco, Cristoforetti, Yvonne, Enriquez-Sarano, Maurice, Pedrazzini, Giovanni
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 04.06.2024; Wiley
• Subjects: Aged; Aged, 80 and over; Cardiac Catheterization; edge‐to‐edge mitral valve repair; Female; Heart Valve Prosthesis Implantation - adverse effects; Heart Valve Prosthesis Implantation - mortality; Humans; Life Expectancy; Male; Middle Aged; mitral regurgitation; Mitral Valve - diagnostic imaging; Mitral Valve - physiopathology; Mitral Valve - surgery; Mitral Valve Insufficiency - mortality; Mitral Valve Insufficiency - physiopathology; Mitral Valve Insufficiency - surgery; mortality; Original Research; percutaneous mitral valve repair; Registries; Risk Factors; sex; Sex Factors; Time Factors; Treatment Outcome; mortality; edge‐to‐edge mitral valve repair; mitral regurgitation; percutaneous mitral valve repair; sex
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.123.032706

Currently, no clear impact of sex on short- and long-term survival following transcatheter edge-to-edge mitral valve repair (TEER) is evident, although no data are available on postprocedural life expectancy. Our aim was to assess sex-specific differences in outcomes of patients with mitral regurgitation (MR) treated by TEER. Short-term and 5-year outcomes in men and women undergoing TEER between 2011 and 2018 who were included in the large, multicenter, real-world MitraSwiss registry were analyzed. Outcomes were compared stratified by sex and according to MR cause (primary versus secondary). The impact of TEER on postprocedural life expectancy was estimated by relative survival analysis. Among 1142 patients aged 60 to 89 years, 39.8% were women. They were older, with fewer cardiovascular risk factors and lower functional capacity compared with men. Thirty-day mortality was higher in men than in women (3.3% versus 1.1%; odds ratio, 3.16 [95% CI, 1.16-10.7]; =0.020). Five-year survival was comparable in both sexes (adjusted hazard ratio for 5-year mortality in men, 1.14 [95% CI, 0.90-1.44], =0.275). Both men and women with either primary or secondary MR showed similar clinical efficacy over time. TEER provided high relative survival estimates among all groups, and fully restored predicted life expectancy in women with primary MR (5-year relative survival estimate, 97.4% [95% CI, 85.5-107.0]). TEER is not associated with increased short-term mortality in women, whereas 5-year outcomes are comparable between sexes. Moreover, TEER completely restored normal life expectancy in women with primary MR. A residual excess mortality persists in secondary MR, independently of sex.